Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Ifosfamide/Vinorelbine in Refractory/Recurrent Hodgkin Lymphoma
NCT00381940Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Primary endpoint: Complete Response. Started Jan 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00381940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381940.